Future medicine shaped by an interdisciplinary new biology

The projected effects of the new biology on future medicine are described. The new biology is essentially the result of shifts in the way biological research has progressed over the past few years, mainly through the involvement of physical scientists and engineers in biological thinking and research with the establishment of new teams and task forces to address the new challenges in biology. Their contributions go well beyond the historical contributions of mathematics, physical sciences, and engineering to medical practice that were largely equipment oriented. Over the next generation, the entire fabric of the biosciences will change as research barriers between disciplines diminish and eventually cease to exist. The resulting effects are starting to be noticed in front-line medicine and the prospects for the future are immense and potentially society changing. The most likely disciplines to have early effects are outlined and form the main thrust of this paper, with speculation about other disciplines and emphasis that although physics-based and engineering-based biology will change future medicine, the physical sciences and engineering will also be changed by these developments. Essentially, physics is being redefined by the need to accommodate these new views of what constitutes biological systems and how they function.

[1]  G. West,et al.  The importance of quantitative systemic thinking in medicine , 2012, The Lancet.

[2]  Jessica Melin,et al.  Microfluidic large-scale integration: the evolution of design rules for biological automation. , 2007, Annual review of biophysics and biomolecular structure.

[3]  Stephen F Keevil,et al.  Physics and medicine: a historical perspective , 2012, The Lancet.

[4]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[5]  Marshall McLuhan,et al.  The medium is the message , 2005 .

[6]  Joshua D. Knowles,et al.  Closed-loop, multiobjective optimization of analytical instrumentation: gas chromatography/time-of-flight mass spectrometry of the metabolomes of human serum and of yeast fermentations. , 2005, Analytical chemistry.

[7]  E. Berner,et al.  Clinical Decision Support Systems: Theory and Practice , 1998 .

[8]  Douglas B Kell,et al.  The virtual human: Towards a global systems biology of multiscale, distributed biochemical network models , 2007, IUBMB life.

[9]  L. Stein.  Creating a bioinformatics nation , 2002, Nature.

[10]  Denis Noble,et al.  Biophysics and systems biology , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[11]  J. Farrar,et al.  Advances in clinical research methodology for pain clinical trials , 2010, Nature Medicine.

[12]  W. Xi,et al.  Self-propelled nanotools. , 2012, ACS nano.

[13]  Paul Davidovits,et al.  Physics in Biology and Medicine , 1975 .

[14]  D. Kell,et al.  Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  William L. Barnes,et al.  Shedding light on life , 2008 .

[16]  L. Hood,et al.  A personal journey of discovery: developing technology and changing biology. , 2008, Annual review of analytical chemistry.

[17]  T. Ideker,et al.  A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.

[18]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[19]  J. B. Birks,et al.  Rutherford at Manchester , 1963 .

[20]  Lucy Fairclough,et al.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease , 2009, Respiratory research.

[21]  Peter V Coveney,et al.  Patient-specific simulation as a basis for clinical decision-making , 2008, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[22]  Christophe Lemetre,et al.  Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. , 2012, Journal of Alzheimer's disease : JAD.

[23]  Scott E McNeil,et al.  Nanotechnology for the biologist , 2005, Journal of leukocyte biology.

[24]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[25]  Esther F. Schmid,et al.  Keynote review: Is declining innovation in the pharmaceutical industry a myth? , 2005, Drug discovery today.

[26]  Y. Lazebnik.  Can a biologist fix a radio? -- Or, what I learned while studying apoptosis, (Cancer Cell. 2002 Sep;2(3):179-82). , 2002, Biochemistry. Biokhimiia.

[27]  Douglas B. Kell,et al.  Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.

[28]  Alfred Cuschieri,et al.  The importance of physics to progress in medical treatment , 2012, The Lancet.

[29]  Z. Wang.  Self‐Powered Nanosensors and Nanosystems , 2012, Advanced materials.

[30]  D. Kell.  Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.

[31]  Pedro Mendes,et al.  The markup is the model: reasoning about systems biology models in the Semantic Web era. , 2008, Journal of theoretical biology.

[32]  Paul Davidovits.  Comprar Physics in Biology and Medicine | Paul Davidovits | 9780123694119 | Academic Press , 2008 .

[33]  Y. Lazebnik.  Can a biologist fix a radio? — or, what I learned while studying apoptosis , 2004, Biochemistry (Moscow).

[34]  Nin Bajaj,et al.  Plasmonic-array-based biosensors for the diagnosis of neurodegenerative diseases , 2011, 2011 Functional Optical Imaging.

[35]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[36]  M C Davies,et al.  Measuring and visualizing single molecular interactions in biology. , 2003, Biochemical Society transactions.

[37]  T. Hankemeier,et al.  Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? , 2006, Pharmacogenomics.